These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21976121)

  • 1. [Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)].
    Rexer H
    Urologe A; 2011 Oct; 50(10):1319-21. PubMed ID: 21976121
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
    Powles T
    Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib for the treatment of renal cancer.
    Strumberg D
    Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
    Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in renal cell carcinoma.
    Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
    Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
    Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
    Hutson TE
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.